Fintel on MSN4d
Maxim Group Upgrades Moleculin Biotech (MBRX)
Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to ...
Fintel on MSN8d
Maxim Group Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation
Fintel reports that on March 21, 2025, Maxim Group initiated coverage of Anixa Biosciences (NasdaqCM:ANIX) with a Buy ...
Maxim Group Reaffirms “Hold” Rating for CNS Pharmaceuticals (NASDAQ:CNSP)
Maxim Group reissued their hold rating on shares of CNS Pharmaceuticals (NASDAQ:CNSP – Free Report) in a report issued on ...
Nasdaq11d
Maxim Group Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation
Fintel reports that on March 21, 2025, Maxim Group initiated coverage of Anixa ... technologies in complementary fields for further development and commercialization. Fintel is one of the most ...